UPDATE On Levadex, a new formulation of dihydroergotamine which is given as an oral inhalation,

May 21st, 2011 - Posted by Lisa Erwin

Levadex, a new formulation of dihydroergotamine which is given as an oral inhalation, has been shown in a phase III clinical trials to provide quick and sustained pain relief for migraine attacks. Dihydroergotamine (DHE) is in a class of medications called ergot alkaloids. It works by tightening blood vessels in the brain and by stopping the release of natural substances in the brain that cause swelling. While this formulation is new, DHE is not a new drug and is currently available in other dosage forms including as an injection for hospital administration as well as a nasal spray. MAP pharmaceuticals has been testing the new formulation of the drug for eventual introduction into the market as a new alternative for patients in need of rapid and prolonged relief of headache pain and other migraine symptoms.

http://migraine.com/blog/updated-information-on-new-migraine-formulation/

That's interesting..DHE in the UK is only administered under hospital supervision currently, due to potential complications in a small number of patients...I wonder if the inhaled medication would be available more generally?

However i think it would be restricted to low risk individuals if it was..it's a potentially difficult drug and I would be interested to know how much of the meds you'd be limited to take over what period of time etc.

Jane